Severe neurologic complications after hematopoietic stem cell transplantation in children

被引:78
作者
Faraci, M
Lanino, E
Dini, G
Fondelli, MP
Morreale, G
Dallorso, S
Manzitti, C
Calevo, MG
Gaggero, R
Castagnola, E
Haupt, R
机构
[1] G Gaslini Childrens Res Inst, Bone Marrow Transplant Unit, Dept Hematol Oncol, I-16147 Genoa, Italy
[2] G Gaslini Childrens Res Inst, Sci Directorate, Epidemiol & Biostat Sect, I-16147 Genoa, Italy
[3] G Gaslini Childrens Res Inst, Infect Dis Unit, I-16147 Genoa, Italy
关键词
D O I
10.1212/01.WNL.0000036608.42104.B9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To describe and evaluate the incidence and risk factors of severe neurologic events (SNE) in pediatric recipients of allogeneic or autologous hematopoietic stem cell transplantation (HSCT) for hematologic or nonhematologic diseases. Methods: Retrospective analysis of 272 consecutive children admitted to the G. Gaslini Children's Research Institute and given HSCT (70 from unrelated donors, 115 from related donors, and 87 autologous) between June 1985 and January 2001. Results: Thirty-seven children (13.6%) developed SNE after a median of 90 days (range, 5 days to 8.8 years) after HSCT. Cyclosporine A (CSA) neurotoxicity was the most frequent SNE (n = 21), followed by irradiation or chemotherapy injury (n = 7), CNS infections (n = 7), cerebrovascular events (n = 3), and immune-mediated etiology SNE (n = 2). Eleven patients (30%) died because of the neurologic complications. Type of HSCT, treatment with total body irradiation (TBI), acute graft-vs-host disease (GvHD), GvHD >grade 2, and treatment with CSA were associated with a significant increased risk of SNE. Conclusions: Severe neurologic complications are frequent (14%) among children receiving HSCT, causing 8.5% of deaths after transplant. Transplant from allogeneic donor, especially if unrelated, the development of severe acute GvHD grade >2, and the use of TBI in the preparative regimen are the main risk factors for such complications.
引用
收藏
页码:1895 / 1904
页数:10
相关论文
共 35 条
[1]   Early neurologic complications following allogeneic bone marrow transplant for leukemia - A prospective study [J].
Antonini, G ;
Ceschin, V ;
Morino, S ;
Fiorelli, M ;
Gragnani, F ;
Mengarelli, A ;
Iori, AP ;
Arcese, W .
NEUROLOGY, 1998, 50 (05) :1441-1445
[2]   Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases [J].
Bleggi-Torres, LF ;
de Medeiros, BC ;
Werner, B ;
Neto, JZ ;
Loddo, G ;
Pasquini, R ;
de Medeiros, CR .
BONE MARROW TRANSPLANTATION, 2000, 25 (03) :301-307
[3]  
BRUZZONE MG, 2001, TXB MAGNETIC RESONAN, P715
[4]   COTRIMOXAZOLE THERAPY OF TOXOPLASMA-GONDII ENCEPHALITIS IN AIDS PATIENTS [J].
CANESSA, A ;
DELBONO, V ;
DELEO, P ;
PIERSANTELLI, N ;
TERRAGNA, A .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (02) :125-130
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   Solid cancers after bone marrow transplantation [J].
Curtis, RE ;
Rowlings, PA ;
Deeg, HJ ;
Shriner, DA ;
Socie, G ;
Travis, LB ;
Horowitz, MM ;
Witherspoon, RP ;
Hoover, RN ;
Sobocinski, KA ;
Fraumeni, JF ;
Boice, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) :897-904
[7]   Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors [J].
de Brabander, C ;
Cornelissen, J ;
Smitt, PAES ;
Vecht, CJ ;
van den Bent, MJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (01) :36-40
[8]  
Gallardo D, 1996, BONE MARROW TRANSPL, V18, P1135
[9]   Cyclosporine neurotoxicity: a review [J].
Gijtenbeek, JMM ;
van den Bent, MJ ;
Vecht, CJ .
JOURNAL OF NEUROLOGY, 1999, 246 (05) :339-346
[10]   Cyclosporin A acute encephalopathy and seizure syndrome in childhood: Clinical features and risk of seizure recurrence [J].
Gleeson, JG ;
duPlessis, AJ ;
Barnes, PD ;
Riviello, JJ .
JOURNAL OF CHILD NEUROLOGY, 1998, 13 (07) :336-344